Cash flow Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-03-09 EDT			5-day change	1st Jan Change
3,389.00 ^JPY	-1.80%		-7.51%	+19.29%

03-04	Nxera Pharma Co., Ltd. Submits Marketing Authorization Application For Daridorexant In South Korea	CI
03-04	Nxera Submits South Korea Filing for Insomnia Drug Daridorexant	MT

dc53e4c845.yTv6nrm8JkXJc3UYWhg-2fvTGWd7lgru4sHEdzW_O_E.-XOJ2-zjcz-lPTZMaEhR4JbheA8XrmWHoaCOGQTof8Kzcqjr-98QEZggBg

Published financial data: SHIONOGI & CO., LTD.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2021	2022	2023	2024	2025
Revenues	297B	335B	427B	435B	438B
Total Revenues	297B	335B	427B	435B	438B
Cost of Goods Sold, Total	52.52B	55.42B	62.25B	57.6B	63.83B
Gross Profit	245B	280B	364B	377B	374B
Selling General & Admin Expenses, Total	88.39B	87.88B	93.64B	94.99B	97.06B
R&D Expenses	54.25B	73B	102B	103B	109B
Depreciation & Amortization - (IS)	6.72B	7.37B	7.86B	8.39B	8.99B
Other Operating Expenses	2.46B	813M	1.3B	3.08B	455M
Other Operating Expenses, Total	152B	169B	205B	209B	215B
Operating Income	92.83B	111B	159B	168B	159B
Interest Expense, Total	-256M	-349M	-91M	-163M	-338M
Interest And Investment Income	25.49B	14.68B	68.69B	48.44B	52.39B
Net Interest Expenses	25.23B	14.33B	68.6B	48.27B	52.06B
Currency Exchange Gains (Loss)	923M	1.9B	1.9B	2.76B	-1B
Other Non Operating Income (Expenses)	-578M	-269M	827M	-1.13B	-1.15B
EBT, Excl. Unusual Items	118B	127B	231B	218B	209B
Restructuring Charges	-	-	-	-7.26B	-860M
Gain (Loss) On Sale Of Investments	2.96B	-20M	-33M	-123M	-768M
Gain (Loss) On Sale Of Assets	22.94B	-87M	1.63B	633M	-629M
Asset Writedown	-825M	-141M	-11.76B	-13.19B	-6.01B
Legal Settlements	-464M	-106M	-80M	-59M	-208M
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	143B	126B	220B	198B	201B
Income Tax Expense	30.96B	12.83B	35.84B	37.71B	31.22B
Earnings From Continuing Operations	112B	113B	184B	161B	170B
Net Income to Company	112B	113B	184B	161B	170B
Minority Interest	-203M	746M	469M	1.46B	900M
Net Income - (IS)	112B	114B	185B	162B	170B
Net Income to Common Incl Extra Items	112B	114B	185B	162B	170B
Net Income to Common Excl. Extra Items	112B	114B	185B	162B	170B
Per Share Items
Net EPS - Basic	121.67	126.25	207.1	186.17	200.36
Basic EPS - Continuing Operations	121.67	126.25	207.1	186.17	200.36
Basic Weighted Average Shares Outstanding	919M	904M	893M	870M	851M
Net EPS - Diluted	121.63	126.21	207.03	186.11	200.29
Diluted EPS - Continuing Operations	121.63	126.21	207.03	186.11	200.29
Diluted Weighted Average Shares Outstanding	920M	905M	893M	871M	851M
Normalized Basic EPS	80.28	88.33	161.88	158.42	154.79
Normalized Diluted EPS	80.25	88.3	161.83	158.37	154.73
Dividend Per Share	36	38.33	45	53.33	61.33
Payout Ratio	29.08	29.03	19.54	27.08	28.57
American Depositary Receipts Ratio (ADR)	0.5	0.5	0.5	0.5	0.5
Supplemental Items
EBITDA	108B	127B	176B	187B	180B
EBITA	92.83B	111B	159B	168B	159B
EBIT	92.83B	111B	159B	168B	159B
Effective Tax Rate - (Ratio)	21.64	10.16	16.26	19.02	15.55
Normalized Net Income	73.8B	79.88B	145B	138B	132B
Non-Cash Pension Expense	-4.42B	-4.35B	-4.4B	-4.09B	-3.9B
Supplemental Operating Expense Items
Advertising Expense	13.04B	9.98B	7.52B	13.91B	13.15B
Selling and Marketing Expenses	13.04B	9.98B	7.52B	13.91B	13.15B
Research And Development Expense From Footnotes	54.25B	73B	102B	103B	109B

Fiscal Period: March	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	276B	254B	309B	358B	375B
Short Term Investments	-	-	-	-	-
Total Cash And Short Term Investments	276B	254B	309B	358B	375B
Accounts Receivable, Total	77.98B	123B	110B	123B	121B
Other Receivables	164M	51M	68M	-	-
Total Receivables	78.14B	123B	110B	123B	121B
Inventory	38B	45.89B	57.92B	64.92B	65.48B
Deferred Tax Assets Current	-	-	-	-	-
Other Current Assets, Total	164B	236B	307B	238B	298B
Total Current Assets	556B	659B	784B	784B	859B
Net Property Plant And Equipment	95.71B	112B	119B	124B	135B
Long-term Investments	249B	275B	281B	362B	369B
Goodwill	9.36B	9.64B	9.82B	15.29B	15.75B
Other Intangibles, Total	76.56B	81.22B	96.31B	118B	144B
Deferred Tax Assets Long-Term	11.73B	12.91B	22.1B	13.53B	13.24B
Other Long-Term Assets, Total	4M	5M	4M	6M	4M
Total Assets	999B	1,151B	1,312B	1,417B	1,535B
Liabilities
Accounts Payable, Total	9.9B	16.37B	14B	14.81B	13.58B
Accrued Expenses, Total	-	-	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	3.38B	2.94B	3.01B	2.87B	3.46B
Current Income Taxes Payable	28.03B	17.97B	42.22B	20.84B	22.4B
Other Current Liabilities	58.87B	87.11B	99.32B	95.39B	89.95B
Total Current Liabilities	100B	124B	159B	134B	129B
Long-Term Debt	-	-	-	-	-
Long-Term Leases	4.61B	3.73B	6.4B	8.75B	18.42B
Pension & Other Post Retirement Benefits	16.32B	15.41B	12.87B	7.99B	8.02B
Deferred Tax Liability Non Current	7.75B	7.81B	5.92B	4.36B	4.4B
Other Non Current Liabilities	5.59B	5.97B	6.19B	9.34B	12.62B
Total Liabilities	134B	157B	190B	164B	173B
Common Stock, Total	21.28B	21.28B	21.28B	21.28B	21.28B
Additional Paid In Capital	13.73B	14.46B	15.2B	14.24B	17.84B
Retained Earnings	752B	833B	941B	1,066B	1,116B
Treasury Stock	-57.99B	-57.86B	-63.07B	-138B	-65.86B
Comprehensive Income and Other	117B	165B	186B	272B	273B
Total Common Equity	846B	976B	1,100B	1,235B	1,362B
Minority Interest	18.44B	17.62B	21.83B	17.24B	572M
Total Equity	865B	993B	1,122B	1,253B	1,362B
Total Liabilities And Equity	999B	1,151B	1,312B	1,417B	1,535B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	904M	904M	883M	850M	851M
ECS Total Common Shares Outstanding	904M	904M	883M	850M	851M
Book Value / Share	935.56	1.08K	1.25K	1.45K	1.6K
Tangible Book Value	760B	885B	994B	1,102B	1,203B
Tangible Book Value Per Share	840.56	978.28	1.13K	1.3K	1.41K
Total Debt	7.99B	6.67B	9.41B	11.62B	21.88B
Net Debt	-268B	-248B	-300B	-346B	-353B
Debt Equivalent of Unfunded Proj. Benefit Obligation	-19.36B	-22.04B	-23.73B	-32B	-31.8B
Minority Interest, Total (Incl. Fin. Div)	18.44B	17.62B	21.83B	17.24B	572M
Inventories - Raw Materials, Total	10.61B	14.04B	18.27B	17.22B	17.27B
Inventories - Work In Process, Total	7.81B	15.12B	22.96B	25.46B	22.25B
Inventories - Finished Goods, Total	19.58B	16.73B	16.68B	22.23B	25.96B
Inventories - Others	-	1M	1M	-	1M
Full Time Employees	5.48K	5.69K	5.68K	4.96K	4.96K
Accumulated Allowance for Doubtful Accounts (Supple)	71M	50M	48M	83M	547M

Fiscal Period: March	2021	2022	2023	2024	2025
Net Income	143B	126B	220B	198B	201B
Depreciation & Amortization - CF	14.78B	16.35B	17.16B	18.32B	20.93B
Amortization of Goodwill and Intangible Assets - (CF)	-	-	-	-	-
Depreciation & Amortization, Total	14.78B	16.35B	17.16B	18.32B	20.93B
(Gain) Loss From Sale Of Asset	825M	141M	11.76B	8.26B	254M
(Gain) Loss on Sale of Investments - (CF)	-	-	-	-	-
Other Operating Activities, Total	-30.24B	-16.92B	-49.12B	-59.34B	-32.22B
Change In Accounts Receivable	2.99B	-43.42B	13.94B	-12.37B	1.91B
Change In Inventories	-3.44B	-7.13B	-11.7B	-6.34B	-388M
Change In Accounts Payable	-2.38B	11.69B	7.74B	-5.82B	-1.7B
Change in Other Net Operating Assets	-16.52B	15.09B	-32.24B	13.29B	5.92B
Cash from Operations	109B	102B	178B	154B	195B
Capital Expenditure	-28.18B	-26.18B	-11.86B	-12.69B	-17.13B
Sale of Property, Plant, and Equipment	45M	-	-	-	-
Cash Acquisitions	-3.64B	-	-	-27.2B	-1.32B
Divestitures	-	-	-	-296M	-
Sale (Purchase) of Intangible assets	-4.76B	-5.38B	-25.33B	-15.57B	-34.98B
Investment in Marketable and Equity Securities, Total	35.02B	-65.58B	-14.41B	64.55B	-60.8B
Other Investing Activities, Total	-3.74B	940M	3.31B	-2.86B	-1.85B
Cash from Investing	-5.26B	-96.2B	-48.29B	5.92B	-116B
Long-Term Debt Repaid, Total	-	-	-	-	-
Total Debt Repaid	-	-	-	-	-
Issuance of Common Stock	33.53B	-	-	-	-
Repurchase of Common Stock	-50.13B	-14M	-49.54B	-75.18B	-10M
Common Dividends Paid	-32.53B	-33.15B	-36.14B	-43.88B	-48.7B
Common & Preferred Stock Dividends Paid	-32.53B	-33.15B	-36.14B	-43.88B	-48.7B
Other Financing Activities, Total	5.24B	-3.46B	1.56B	-7.8B	-16.2B
Cash from Financing	-43.89B	-36.62B	-84.12B	-127B	-64.91B
Foreign Exchange Rate Adjustments	7.42B	9B	9.35B	15.51B	2.23B
Miscellaneous Cash Flow Adjustments	-	1M	-1M	1M	-1M
Net Change in Cash	67.31B	-21.75B	54.8B	48.87B	16.7B
Supplemental Items
Cash Interest Paid	256M	87M	94M	164M	305M
Cash Income Tax Paid (Refund)	32.25B	26.04B	27.28B	63.64B	31.82B
Levered Free Cash Flow	85.84B	-46.33B	43.36B	120B	5.49B
Unlevered Free Cash Flow	86B	-46.12B	43.41B	120B	5.7B
Change In Net Working Capital	-46.14B	100B	36.1B	-24.36B	62.71B
Net Debt Issued / Repaid	-	-	-	-	-

Fiscal Period: March	2021	2022	2023	2024	2025
Profitability
Return on Assets	6.2	6.44	8.08	7.71	6.75
Return on Total Capital	7.05	7.39	9.34	8.79	7.52
Return On Equity %	13.76	12.21	17.44	13.53	12.97
Return on Common Equity	13.89	12.54	17.82	13.88	13.12
Margin Analysis
Gross Profit Margin %	82.33	83.46	85.41	86.76	85.44
SG&A Margin	29.74	26.22	21.95	21.83	22.15
EBITDA Margin %	36.21	37.9	41.35	42.91	41.13
EBITA Margin %	31.24	33.02	37.32	38.7	36.35
EBIT Margin %	31.24	33.02	37.32	38.7	36.35
Income From Continuing Operations Margin %	37.71	33.85	43.24	36.91	38.68
Net Income Margin %	37.64	34.07	43.35	37.24	38.89
Net Avail. For Common Margin %	37.64	34.07	43.35	37.24	38.89
Normalized Net Income Margin	24.83	23.84	33.88	31.69	30.04
Levered Free Cash Flow Margin	28.88	-13.83	10.16	27.48	1.25
Unlevered Free Cash Flow Margin	28.94	-13.76	10.17	27.5	1.3
Asset Turnover
Asset Turnover	0.32	0.31	0.35	0.32	0.3
Fixed Assets Turnover	3.46	3.22	3.69	3.59	3.39
Receivables Turnover (Average Receivables)	3.77	3.34	3.67	3.74	3.6
Inventory Turnover (Average Inventory)	1.46	1.32	1.2	0.94	0.98
Short Term Liquidity
Current Ratio	5.55	5.3	4.95	5.86	6.63
Quick Ratio	3.54	3.03	2.64	3.59	3.83
Operating Cash Flow to Current Liabilities	1.09	0.82	1.12	1.15	1.51
Days Sales Outstanding (Average Receivables)	96.85	109.42	99.55	97.84	101.35
Days Outstanding Inventory (Average Inventory)	249.55	276.29	304.36	390.24	372.84
Average Days Payable Outstanding	66.5	75.75	74.64	81.62	80.46
Cash Conversion Cycle (Average Days)	279.9	309.97	329.27	406.46	393.72
Long Term Solvency
Total Debt/Equity	0.92	0.67	0.84	0.93	1.61
Total Debt / Total Capital	0.92	0.67	0.83	0.92	1.58
LT Debt/Equity	0.53	0.38	0.57	0.7	1.35
Long-Term Debt / Total Capital	0.53	0.37	0.57	0.69	1.33
Total Liabilities / Total Assets	13.46	13.67	14.48	11.6	11.26
EBIT / Interest Expense	362.62	317.1	1.75K	1.03K	471.37
EBITDA / Interest Expense	420.35	363.95	1.94K	1.15K	533.3
(EBITDA - Capex) / Interest Expense	310.27	288.92	1.81K	1.07K	482.64
Total Debt / EBITDA	0.07	0.05	0.05	0.06	0.12
Net Debt / EBITDA	-2.49	-1.95	-1.7	-1.86	-1.96
Total Debt / (EBITDA - Capex)	0.1	0.07	0.06	0.07	0.13
Net Debt / (EBITDA - Capex)	-3.38	-2.46	-1.82	-1.99	-2.16
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-10.86	12.77	27.32	1.97	0.73
Gross Profit, 1 Yr. Growth %	-11.55	14.33	30.29	3.58	-0.8
EBITDA, 1 Yr. Growth %	-23.95	18.04	38.89	5.83	-3.45
EBITA, 1 Yr. Growth %	-27.12	19.21	43.9	5.73	-5.38
EBIT, 1 Yr. Growth %	-27.12	19.21	43.9	5.73	-5.38
Earnings From Cont. Operations, 1 Yr. Growth %	-8.29	1.23	62.64	-12.97	5.58
Net Income, 1 Yr. Growth %	-8.46	2.08	61.99	-12.4	5.19
Normalized Net Income, 1 Yr. Growth %	-24.01	8.24	80.98	-4.63	-4.51
Diluted EPS Before Extra, 1 Yr. Growth %	-7.69	3.77	64.04	-10.11	7.62
Accounts Receivable, 1 Yr. Growth %	-2.2	57.7	-10.73	11.89	-1.85
Inventory, 1 Yr. Growth %	12.38	20.76	26.21	12.08	0.86
Net Property, Plant and Equip., 1 Yr. Growth %	25.92	17.46	5.47	4.6	8.69
Total Assets, 1 Yr. Growth %	14.63	15.18	14.01	8.01	8.36
Tangible Book Value, 1 Yr. Growth %	7.5	16.39	12.33	10.92	9.08
Common Equity, 1 Yr. Growth %	10.67	15.31	12.75	12.3	10.25
Cash From Operations, 1 Yr. Growth %	-17.36	-6.39	74.26	-13.26	26.69
Capital Expenditures, 1 Yr. Growth %	215.06	-7.09	-54.71	7.04	34.92
Levered Free Cash Flow, 1 Yr. Growth %	-185.05	-153.98	-193.57	175.74	-95.41
Unlevered Free Cash Flow, 1 Yr. Growth %	-185.4	-153.62	-194.14	175.61	-95.23
Dividend Per Share, 1 Yr. Growth %	4.85	6.48	17.39	18.52	14.99
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-9.61	0.26	19.82	13.94	1.35
Gross Profit, 2 Yr. CAGR %	-11	0.56	22.05	16.17	1.36
EBITDA, 2 Yr. CAGR %	-17.4	-5.25	28.04	21.24	1.08
EBITA, 2 Yr. CAGR %	-18.93	-6.79	30.98	23.35	0.02
EBIT, 2 Yr. CAGR %	-18.14	-6.79	30.98	23.35	0.02
Earnings From Cont. Operations, 2 Yr. CAGR %	-8.31	-3.65	28.31	18.98	-4.14
Net Income, 2 Yr. CAGR %	-8.21	-3.33	28.59	19.12	-4.01
Normalized Net Income, 2 Yr. CAGR %	-15.86	-9.31	39.96	31.38	-4.57
Diluted EPS Before Extra, 2 Yr. CAGR %	-6.87	-2.13	30.47	21.43	-1.64
Accounts Receivable, 2 Yr. CAGR %	8.8	24.19	18.65	-0.05	4.79
Inventory, 2 Yr. CAGR %	-2.66	16.49	23.45	18.93	6.32
Net Property, Plant and Equip., 2 Yr. CAGR %	13.23	21.62	11.3	5.04	6.63
Total Assets, 2 Yr. CAGR %	13.26	14.9	14.59	10.97	8.19
Tangible Book Value, 2 Yr. CAGR %	11.34	11.86	14.34	11.62	9.99
Common Equity, 2 Yr. CAGR %	12.54	12.96	14.02	12.52	11.27
Cash From Operations, 2 Yr. CAGR %	-13.49	-12.05	27.72	22.95	4.83
Capital Expenditures, 2 Yr. CAGR %	107.46	71.09	-35.13	-30.38	20.18
Levered Free Cash Flow, 2 Yr. CAGR %	-13.17	-32.24	-28.93	60.63	-64.41
Unlevered Free Cash Flow, 2 Yr. CAGR %	-13.23	-32.33	-28.95	61.07	-63.76
Dividend Per Share, 2 Yr. CAGR %	7.19	5.66	11.8	17.95	16.74
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-4.82	-2.69	8.57	13.55	9.36
Gross Profit, 3 Yr. CAGR %	-3.32	-3.25	9.63	15.55	10.21
EBITDA, 3 Yr. CAGR %	-7.1	-6.97	7.63	20.16	12.38
EBITA, 3 Yr. CAGR %	-7.75	-7.81	7.73	21.95	12.92
EBIT, 3 Yr. CAGR %	-6.95	-7.21	7.73	21.95	12.92
Earnings From Cont. Operations, 3 Yr. CAGR %	0.99	-5.24	14.72	12.74	14.33
Net Income, 3 Yr. CAGR %	0.91	-4.9	14.82	13.15	14.28
Normalized Net Income, 3 Yr. CAGR %	-5.38	-8.49	14.18	23.16	18.12
Diluted EPS Before Extra, 3 Yr. CAGR %	2.64	-3.45	16.26	15.23	16.64
Accounts Receivable, 3 Yr. CAGR %	13.59	23.13	11.25	16.35	-0.66
Inventory, 3 Yr. CAGR %	3.14	4.59	19.64	19.54	12.58
Net Property, Plant and Equip., 3 Yr. CAGR %	8.01	14.62	15.98	9.02	6.24
Total Assets, 3 Yr. CAGR %	11.41	13.9	14.6	12.36	10.09
Tangible Book Value, 3 Yr. CAGR %	13.04	13	12.01	13.19	10.77
Common Equity, 3 Yr. CAGR %	12.05	13.46	12.89	13.44	11.76
Cash From Operations, 3 Yr. CAGR %	-5.64	-11.18	10.47	12.27	24.18
Capital Expenditures, 3 Yr. CAGR %	68.6	58.73	9.85	-23.35	-13.2
Levered Free Cash Flow, 3 Yr. CAGR %	15.64	-25.89	-24.55	11.67	-50.88
Unlevered Free Cash Flow, 3 Yr. CAGR %	15.47	-26.09	-24.46	11.64	-50.18
Dividend Per Share, 3 Yr. CAGR %	9.62	6.95	9.44	14	16.96
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-0.84	-0.22	4.36	3.65	5.62
Gross Profit, 5 Yr. CAGR %	0.79	1.39	6.12	4.1	6.25
EBITDA, 5 Yr. CAGR %	0.06	0.4	5.62	3.43	4.96
EBITA, 5 Yr. CAGR %	-0.4	-0.09	6.13	3.58	4.58
EBIT, 5 Yr. CAGR %	0.31	0.46	6.69	3.98	4.58
Earnings From Cont. Operations, 5 Yr. CAGR %	10.96	6.29	11.14	3.79	6.77
Net Income, 5 Yr. CAGR %	10.9	6.36	11.18	4.07	6.88
Normalized Net Income, 5 Yr. CAGR %	3.18	0.61	10.66	5.75	6.27
Diluted EPS Before Extra, 5 Yr. CAGR %	12.59	8.15	12.98	5.83	8.74
Accounts Receivable, 5 Yr. CAGR %	3.66	15.7	15.59	13.27	8.62
Inventory, 5 Yr. CAGR %	-2.06	2.09	10.83	10.11	14.13
Net Property, Plant and Equip., 5 Yr. CAGR %	4	7.37	9.32	10.69	12.14
Total Assets, 5 Yr. CAGR %	9.33	11.41	12.67	12.72	11.99
Tangible Book Value, 5 Yr. CAGR %	11.65	15.44	13.56	12.45	11.2
Common Equity, 5 Yr. CAGR %	10.66	13.29	12.84	13.08	12.24
Cash From Operations, 5 Yr. CAGR %	1.29	-1.82	6.51	1.15	8.18
Capital Expenditures, 5 Yr. CAGR %	28.08	20.2	15.06	14.15	13.87
Levered Free Cash Flow, 5 Yr. CAGR %	2.94	-10.48	-4.82	0.98	-44.14
Unlevered Free Cash Flow, 5 Yr. CAGR %	2.94	-10.6	-4.92	0.93	-43.69
Dividend Per Share, 5 Yr. CAGR %	11.74	9.82	10.49	11.22	12.3